Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 230

Results For "AP"

8349 News Found

Kyverna Therapeutics announces licence agreement with NIH
Biotech | January 04, 2022

Kyverna Therapeutics announces licence agreement with NIH

This next-generation CAR T construct was designed to improve the tolerability profile of conventional CD19 CAR Ts and developed in the laboratory of James N. Kochenderfer, M.D., at the National Cancer Institute, part of the NIH, the same laboratory that discovered axicabtagene ciloleucel


Celltrion announces positive results for its cocktail Covid-19 therapy candidates
Biotech | January 03, 2022

Celltrion announces positive results for its cocktail Covid-19 therapy candidates

Celltrion plans to provide dual treatment options for COVID-19; Regkirona for hospitalised patients and a nebulised cocktail therapy (CT-P63 in combination with Regkirona) for at- home settings


Snapdeal to promote Ayushman Bharat Digital Mission’s Heath ID
Public Health | January 03, 2022

Snapdeal to promote Ayushman Bharat Digital Mission’s Heath ID

The Health ID will allow users to connect with different healthcare providers and enable a consent-based sharing of personal health records


Granules receives ANDA approval for amphetamine mixed salts
Drug Approval | December 30, 2021

Granules receives ANDA approval for amphetamine mixed salts

The current annual U.S. market for amphetamine mixed salts, USP 1.25mg, 1.875mg, 2.5mg, 3.125mg, 3.75mg, 5mg, 7.5mg immediate release tablets strengths is approximately US $ 335 million, according to MAT, Oct 2021 IQVIA/IMS Health


Sanofi loses appeal in the US over Lantus device patents
News | December 30, 2021

Sanofi loses appeal in the US over Lantus device patents

Decisions reaffirm the ability of Biocon Biologics and Viatris to provide patient access to interchangeable Semglee


U.S. FDA approves Leo Pharma’s Adbry
Drug Approval | December 29, 2021

U.S. FDA approves Leo Pharma’s Adbry

Adbry is the first biologic launched by LEO Pharma in the United States and is expected to be available in pharmacies by February 2022


Granules Inc., receives ANDA approval for prazosin hydrochloride
Drug Approval | December 28, 2021

Granules Inc., receives ANDA approval for prazosin hydrochloride

The current annual U.S. market for prazosin hydrochloride 1mg, 2mg, 5mg strengths is approximately US $ 54 million, according to IQVIA/IMS Health


Trastuzumab deruxtecan type II variation application validated by EMA
Biotech | December 28, 2021

Trastuzumab deruxtecan type II variation application validated by EMA

Application based on DESTINY-Breast03 results showing Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan reduced risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1)


NATCO receives approval for the drug for the treatment of Covid-19
Drug Approval | December 28, 2021

NATCO receives approval for the drug for the treatment of Covid-19

Natco Pharma has received approval for Covid 19 drug molnupiravir capsules 200 mg. for Indian market, which will be sold under brand name Molnunat


RaphaCure partners with Zeebon for foraying into North East market
Clinical Trials | December 28, 2021

RaphaCure partners with Zeebon for foraying into North East market

Zeebon is the largest diagnostics services provider in North-Eastern states